Selank Dosage, Protocol, and Reconstitution Guide
Selank
Selank is a synthetic heptapeptide derived from tuftsin, studied primarily for its effects on anxiety, stress response, and cognitive function. Human research has evaluated intranasal Selank in anxiety-related conditions, while additional mechanistic and cognitive research remains limited compared with established therapies.
How It Works
Neurotransmitter + Gene-Expression Signaling → Stress-Response Research → Cognitive + Anxiolytic Research
Selank has been studied for effects on neurotransmitter and gene-expression pathways involved in stress response and cognitive function. Proposed mechanisms include modulation of GABAergic and other signaling systems, but its human effects should not be reduced to a single established pathway.
Selank is commonly discussed for daytime stress support, mood balance, and mental clarity.
It is usually described as calming without being strongly sedating.
It may be used situationally or in short cycles depending on the goal.
Effects can vary based on route of administration and individual stress response.
Selank Protocol
10 mg vial + 3.0 mL BAC Water → 1 unit = 33.3 mcg → Calm Focus + Stress Support
Standard Setup
Vial
10 mg
Water
3.0 mL bacteriostatic water
Concentration
3.33 mg/mL
Conversion
1 unit = 33.3 mcg
Days 1–3
Starting Phase
Dose100 mcg
Units3 units
Volume0.03 mL
Days 4–7
Build Phase
Dose150–200 mcg
Units5–6 units
Volume0.05–0.06 mL
Days 8–14
Standard Range
Dose200–300 mcg
Units6–9 units
Volume0.06–0.09 mL
Optional Higher Range
Advanced Range
Dose300–500 mcg daily
Units9–15 units
Volume0.09–0.15 mL
Advanced Use:
Some users prefer split dosing for more even daytime support, but lower-dose single administration is often the simplest starting point.
Some users prefer split dosing for more even daytime support, but lower-dose single administration is often the simplest starting point.
Protocol Details
Frequency1–2 times daily
TimingMorning or early afternoon
Research-Use Cycle10–14 days
Optional ExtensionUp to 2–4 weeks
Commonly Discussed Break1–2 weeks
Clinical StandardNo universal cycle length or required off-period established
Simple Approach
Selank is commonly discussed in short research-use periods, with lower single-administration amounts providing a simple starting framework before considering increased frequency. Published human research has primarily evaluated intranasal administration, and individual response can vary.
Selank is commonly discussed in short research-use periods, with lower single-administration amounts providing a simple starting framework before considering increased frequency. Published human research has primarily evaluated intranasal administration, and individual response can vary.
How to Use Selank (Timing & Route)
Use Style
Situational or short-cycle support
Timing
Morning or early afternoon
Frequency
1–2 times daily
Most Studied Human Route
Intranasal
Alternative Research-Use Route
Subcutaneous
When & How to Use
Intranasal administration is the route represented in published human Selank research. Subcutaneous protocols discussed in research communities should not be assumed to have equivalent pharmacokinetics, dosing, or clinical evidence.
Daytime administration is commonly discussed in research-use protocols.
Can be used situationally or as a short cycle.
Split dosing may provide steadier effects for some users.
Timing Notes
Morning use is commonly preferred for calm focus and mental clarity.
Early afternoon may work when stress or focus issues increase later in the day.
Evening use may not be ideal for everyone because response can vary.
Track whether Selank feels calming, neutral, focusing, or flattening.
Reconstitution & Dosing (10 mg Vial)
Vial10 mg
Water3.0 mL
Concentration3.33 mg/mL
Conversion1 unit = 33 mcg
Dose Reference
3 units ≈ 100 mcg
6 units ≈ 200 mcg
8 units ≈ 266 mcg
9 units ≈ 300 mcg
15 units ≈ 500 mcg
Reconstitution Steps
Draw 3.0 mL bacteriostatic water
Inject slowly down vial wall
Gently swirl, do not shake
Allow powder to fully dissolve
Label with the reconstitution date
Refrigerate immediately after mixing
Storage & Shelf Life
Storage & Shelf Life
Lyophilized (Unmixed Powder)
Short-term storage: keep refrigerated at 2–8°C
Long-term storage: freezing at −20°C is commonly preferred
Keep the vial sealed until ready to reconstitute
Protect from heat, sunlight, moisture, and repeated temperature swings
Avoid leaving lyophilized peptide at room temperature for extended periods
Do not repeatedly freeze and thaw the same vial
Estimated Unmixed Shelf Life
Refrigerated (2–8°C): commonly ~12–24 months when sealed and dry
Frozen (−20°C): commonly up to ~2–3 years when stored properly
Actual stability depends on supplier quality, handling, and storage conditions
Reconstituted (Mixed)
After mixing: refrigerate at 2–8°C
Use within ~30 days
Do not freeze after mixing
Discard if cloudy, discolored, or if particles appear
Best Practice
Lyophilized peptides are most stable when they stay cold, dry, sealed, and protected from light. Once mixed, the clock starts: keep refrigerated, avoid contamination, and use within the stated window.
Lyophilized peptides are most stable when they stay cold, dry, sealed, and protected from light. Once mixed, the clock starts: keep refrigerated, avoid contamination, and use within the stated window.
Cycle Length & Time Between Cycles
Stress Support Phase → Short Break → Reassess Mood + Focus → Repeat if Needed
Standard Cycle Structure
Research-Use Cycle10–14 days
Primary PhaseStress, mood, focus, and calm support
GoalDaytime calm without sedation
Time Between Cycles
Commonly Discussed Break1–2 weeks
Clinical StandardNo universal cycle length or required off-period established
Allows baseline stress and mood patterns to be reassessed
Helps determine whether benefits continue after stopping
Reduces the chance of continuing without a clear need
Why cycle?
The cycle and break shown here are research-use frameworks rather than universally established clinical requirements. Human Selank studies have used short intranasal treatment periods, but an optimal cycle length or required washout period has not been established across indications.
The cycle and break shown here are research-use frameworks rather than universally established clinical requirements. Human Selank studies have used short intranasal treatment periods, but an optimal cycle length or required washout period has not been established across indications.
When to Stop or Pause Early
Mood feels flat or emotionally muted
Fatigue increases
Headaches become frequent
Focus or calm response fades
You are continuing without a clear stress, mood, or focus goal
Monitoring During Use
Anxiety and stress response
Focus and mental clarity
Mood stability
Daytime calm without sedation
Any flat mood, fatigue, or headaches
Route-specific tolerance, especially nasal irritation if used intranasally
Benefits
Human research has evaluated Selank for anxiety-related symptoms
Studied for effects on stress-response and cognitive signaling
Research has explored potential cognitive effects alongside anxiolytic activity
Intranasal human studies provide some clinical evidence, although the overall evidence base remains limited
Independent large-scale human trials remain lacking
Potential Side Effects
Mild headache
Nasal irritation if used intranasally
Rare fatigue or flat mood if dose is too high
Stacking Strategies
Calm Focus Support → Cognitive Pairing → Avoid Overstimulation
Common Pairing Approaches
Nootropic Stack: Selank + Semax
Stress Support: Selank + DSIP
Focus Stack: Selank + low-dose caffeine
What to Avoid
Stacking too many cognitive compounds at once
Combining with heavy stimulants if anxiety is the main issue
Using high doses if mood feels flat or fatigue increases
Running continuous cycles without reassessing baseline stress and focus
Simple rule
Selank is frequently discussed alongside other cognitive and stress-related compounds, including Semax. Controlled human research has not established specific Selank combination protocols, so evidence for individual compounds should not be interpreted as evidence for a particular stack.
Selank is frequently discussed alongside other cognitive and stress-related compounds, including Semax. Controlled human research has not established specific Selank combination protocols, so evidence for individual compounds should not be interpreted as evidence for a particular stack.
Important Notes
Selank is a synthetic tuftsin-derived heptapeptide studied primarily for anxiety, stress-response, and cognitive effects.
Intranasal administration is the route represented in published human clinical research.
Human evidence exists, but the overall research base remains relatively small.
No universal human dose, cycle length, or required off-period has been established across indications.
Evidence from intranasal studies should not automatically be extrapolated to subcutaneous administration.
Long-term human safety and drug-interaction data remain limited.
Important Disclaimer
Selank is not FDA-approved and is intended for research purposes only.
Research & References
Primary Research
- Konstantinopolsky MA, Chernyakova IV, Kolik LG. Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats. Bulletin of Experimental Biology and Medicine. 2022.
- Zozulya AA, Neznamov GG, Siuniakov TS, et al. Efficacy and Possible Mechanisms of Action of a New Peptide Anxiolytic Selank in the Therapy of Generalized Anxiety Disorders and Neurasthenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2008.
- Volkova A, Shadrina M, Kolomin T, Andreeva L, Limborska S, Myasoedov N, Slominsky P. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology. 2016.
- Panikratova YR, Lebedeva IS, Sokolov OY, et al. Functional Connectomic Approach to Studying Selank and Semax Effects. Doklady Biological Sciences. 2020.
Research Note: Selank is approved as a prescription anxiolytic in Russia but is not approved by the U.S. FDA. Dosing information reflects protocols used in Russian research and clinical settings; nearly all human data originate from Russian institutions, and large multicenter Western clinical trials remain lacking.
Comments
Post a Comment